We aim to make a difference in patient care through our cutting-edge nanotechnology.
We believe that our rapid, laboratory-quality diagnostic solutions enable physicians to make early, appropriate clinical decisions at the point of need.
In less than 10 years, we have demonstrated our ability to bring the company to a stage of full expansion. Currently, our team is composed of 50+ highly skilled employees.
Our dynamic team is highly effective, and we are committed to changing the world of in vitro diagnostics (IVD) by bringing rapid diagnostic solutions close to the patient.
We are committed to creating a positive workplace environment and a culture of trust that support dedicated teamwork.
We believe that the success of a company strongly relies on the happiness of its team members.
"At Abionic we can easily see the impact of our work on the company's growth and this is very motivating". Stéphane Broillet, Head of Engineering.
"What I like most here is the working atmosphere, it's very dynamic and it motivates me to do my best, learn and grow quickly". Alison Papaux, R&D Biology Technician.
abioSCOPE® commercialisation starts
abioSCOPE® CE marked
Sepsis impact study in the United States
Sepsis impact study in 14 ICUs in 4 EU countries
ISO 13485:2016 certification obtained
Fund-raising of 25 million Swiss francs in series C
First allergy panel test FDA registered
Novel biomarker PSP test for sepsis CE marked
Point-of-care ferritin test CE marked
Ambassador of Health Valley Switzerland
Automated production line ISO certified
New facilities inauguration in Biopôle, Lausanne
First prototype allergy panel ready
Fund-raising of 8.2 million Swiss francs in series B
Swiss Excellence Product Award
Fund-raising of 3.5 million Swiss francs in series A
ISO 13485:2003 certification obtained
First demonstration of the technology
Abionic was founded as a spin-off from the EPFL